Novo Nordisk A/S (STU:NOV) Change In Working Capital : €-1,646 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S Change In Working Capital?

Novo Nordisk A/S's change in working capital for the quarter that ended in Dec. 2023 was €-1,299 Mil.

Novo Nordisk A/S's change in working capital for the fiscal year that ended in Dec. 2023 was €-1,643 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Novo Nordisk A/S Change In Working Capital Historical Data

The historical data trend for Novo Nordisk A/S's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Change In Working Capital Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-453.55

-585.11

-1,218.78

-717.25

-1,642.87

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-41.40	-1,372.48	-539.28	1,564.73	-1,299.13

Novo Nordisk A/S Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,646 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Novo Nordisk A/S Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (STU:NOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (STU:NOV) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.